M. Miller

发表

A. Partin, M. Miller, R. Veltri, 2005 .

Quantitative nuclear grade (QNG): A new image analysis‐based biomarker of clinically relevant nuclear structure alterations

R W Veltri, A W Partin, M C Miller, 2000, Journal of cellular biochemistry. Supplement.

Development of secondary structure, growth characteristics and cytogenetic analysis of human transitional cell carcinoma xenografts in scid/scid mice.

P. McCue, R. Veltri, L. Gomella, 1996, The Journal of urology.

Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Alison Stopeck, Massimo Cristofanilli, Leon W M M Terstappen, 2004, The New England journal of medicine.

Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases

Jonathan W. Uhr, J. Uhr, W. J. Allard, 2004, Clinical Cancer Research.

Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer

Leon W.M.M. Terstappen, Daniel F. Hayes, Massimo Cristofanilli, 2006, Clinical Cancer Research.

Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival

G. T. Budd, M. Ellis, D. Hayes, 2006, Clinical Cancer Research.

Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.

Alison Stopeck, Massimo Cristofanilli, Leon W M M Terstappen, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis

Mikhail Gorbounov, Neil M Carleton, Robert W Veltri, 2018, The Prostate.

Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

K. Pienta, C. Parker, H. Scher, 2008, Clinical Cancer Research.

Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

Michael Morse, Nicholas Iannotti, Neal J Meropol, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel.

S. Sleijfer, M. Strijbos, J. Gratama, 2010, European journal of cancer.

Circulating tumor cells predict survival in patients with metastatic prostate cancer.

W. J. Allard, M. Miller, L. Terstappen, 2005, Urology.

Comparative analysis of DNA content in polyomavirus-infected urothelial cells, urothelial dysplasia and high grade transitional cell carcinoma.

B. C. Wright, R. Veltri, Eva M. Wojcik, 1997, Analytical and quantitative cytology and histology.

DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC.

H. Grossman, M. Miller, R. Veltri, 2002, Urologic oncology.

An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level.

D C Young, R W Veltri, R. Badalament, 1996, The Journal of urology.

Original Articles: Prostate Cancer

A. Partin, P. Walsh, J. Epstein, 1995 .

Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease.

A. Partin, P. Walsh, J. Epstein, 1995, The Journal of urology.

PLOIDY ANALYSIS AS A PREDICTOR OF RADICAL PROSTATECTOMY FOR STAGE T2 DISEASE

A. Partin, P. Walsh, J. Epstein, 1995 .

Analysis of repeated biopsy results within 1 year after a noncancer diagnosis.

R W Veltri, M. Miller, R. Veltri, 2000, Urology.

Circulating Tumor Cells Predict Survival Benefit From Treatment in Metastatic Castration-Resistant Prostate Cancer Editorial Comment

Kenneth J. Pienta, Howard I. Scher, J. S. De Bono, 2009 .

Nuclear roundness variance predicts prostate cancer progression, metastasis, and death: A prospective evaluation with up to 25 years of follow‐up after radical prostatectomy

Robert W Veltri, Alan W Partin, A. Partin, 2010, The Prostate.

Ability to Predict Metastasis Based On Pathology Findings and Alterations in Nuclear Structure Of Normal-Appearing and Cancer Peripheral Zone Epithelium in the Prostate

Jonathan I. Epstein, Robert W. Veltri, Alan W. Partin, 2004, Clinical Cancer Research.

Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy

Robert W Veltri, Alan W Partin, A. Partin, 2003, Cancer.

Comparison of logistic regression and neural net modeling for prediction of prostate cancer pathologic stage.

Robert W Veltri, Alan W Partin, A. Partin, 2002, Clinical chemistry.

Prediction of prostate carcinoma stage by quantitative biopsy pathology

R W Veltri, A W Partin, A. Partin, 2001, Cancer.

Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei.

R W Veltri, A W Partin, A. Partin, 1996, Urology.

Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer.

R. Vessella, M. Miller, R. Veltri, 1999, Urology.

Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice.

O. Stoetzer, U. Jaehde, T. Bertsch, 2016, Clinical colorectal cancer.

Monitoring apoptosis and Bcl‐2 on circulating tumor cells in patients with metastatic breast cancer

D. Hayes, G. Doyle, M. Miller, 2013, Molecular oncology.

Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.

C. Punt, J. Picus, L. Terstappen, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.

Steven J Skates, Richard G. Moore, R. Bast, 2010, American journal of obstetrics and gynecology.

Development ofCirculatingTumorCell-Endocrine Therapy Index in Patients with Hormone Receptor – Positive Breast Cancer

Dafydd G. Thomas, D. Hayes, J. Rae, 2015 .

Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor–Positive Breast Cancer

K. Griffith, Dafydd G. Thomas, D. Hayes, 2014, Clinical Cancer Research.

Genetic variability in susceptibility and response to toxicants.

H. Mohrenweiser, D. Bell, M. Miller, 2001, Toxicology letters.

Validation of a Commercial Assay and Decision Support Tool for Routine Paclitaxel Therapeutic Drug Monitoring (TDM)

R. Hilger, U. Jaehde, M. Joerger, 2017, Therapeutic drug monitoring.

Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer.

C. Punt, J. Picus, M. Morse, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study.

Robert W Veltri, M. Miller, R. Veltri, 2003, The Journal of urology.

Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women With a Pelvic Mass

Richard G. Moore, S. Skates, J. Ball, 2011, Obstetrics and gynecology.

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Steven J Skates, Richard G. Moore, R. Bast, 2009, Gynecologic oncology.

Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors.

C. Rao, G. Doyle, M. Miller, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer

G. Doyle, M. Miller, L. Terstappen, 2009, Journal of oncology.

Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer.

C. Punt, J. Picus, M. Morse, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents.

I. Nagtegaal, C. Punt, L. Terstappen, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction.

A. Partin, J. Epstein, E. Humphreys, 2009, Urology.

The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.

Thorsten Verch, Richard G. Moore, R. Bast, 2008, Gynecologic oncology.

The Parsortix™ Cell Separation System—A versatile liquid biopsy platform

M. Miller, D. O'Shannessy, Daniel J. O'Shannessy, 2018, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Prediction of Prostate-Specific Antigen Recurrence in Men with Long-term Follow-up Postprostatectomy Using Quantitative Nuclear Morphometry

Robert W Veltri, Alan W Partin, Danil V Makarov, 2008, Cancer Epidemiology Biomarkers & Prevention.

Stromal–epithelial measurements of prostate cancer in native Japanese and Japanese-American men

A. Partin, M. A. Khan, M. Miller, 2004, Prostate Cancer and Prostatic Diseases.

Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer.

G. Hortobagyi, V. Valero, E. Rohren, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.

G. Hortobagyi, V. Valero, E. Rohren, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States.

M. Miller, R. Veltri, R. Orozco, 1998, Urology.

MESOMARK: a potential test for malignant pleural mesothelioma.

N. Sardesai, H. Pass, W. J. Allard, 2007, Clinical chemistry.

Global gene expression profiling of circulating tumor cells.

K. Pienta, L. Weiner, G. Doyle, 2005, Cancer research.

The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis.

R. Veltri, R. Orozco, G. O'dowd, 1998, Seminars in urologic oncology.

Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia.

M. Kattan, P. Schellhammer, R. Vessella, 1996, Urology.

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases.

A. Stopeck, W. J. Allard, C. Rao, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival

Leonie L. Zeune, H. Groen, J. Bono, 2020, British Journal of Cancer.

Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas

C. Rao, G. Doyle, M. Miller, 2007, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations.

M. Miller, R. Veltri, M. Miller, 1999, Urology.

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).

N. Reinmuth, Y. Ko, T. Gauler, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells.

M. Willingham, M. Miller, W. Fan, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.

A. Partin, M. Miller, R. Veltri, 2001, Urology.

EVALUATION OF VARIOUS MOLECULAR FORMS OF PSA TO DISTINGUISH BENIGN PROSTATIC HYPERPLASIA (BPH) FROM PROSTATE CANCER (CaP)

George L. Wright, R. Veltri, Gang Zhao, 1999 .

Update on the appropriate staging evaluation for newly diagnosed prostate cancer.

J. Oesterling, M. Miller, R. Veltri, 1997, The Journal of urology.

Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer.

A. Partin, M. Miller, R. Veltri, 2002, Urology.

HE4 (WFDC2) gene overexpression promotes ovarian tumor growth

Richard G. Moore, E. Hill, G. Lambert-Messerlian, 2014, Scientific Reports.

Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women.

R. Knapp, K. Holcomb, M. Miller, 2011, American journal of obstetrics and gynecology.

Alterations in nuclear structure and expression of proPSA predict differences between native Japanese and Japanese-American prostate cancer.

A. Partin, Cameron Marlow, R. Veltri, 2006, Urology.

Review Article UPDATE ON THE APPROPRIATE STAGING EVALUATION FOR NEWLY DIAGNOSED PROSTATE CANCER

J. Oesterling, M. Miller, R. Veltri, 1997 .

Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy.

R W Veltri, A W Partin, A. Partin, 1999, Urology.

A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype

Hui Zhang, J. Epstein, S. Hewitt, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Circulating tumor cells (CTC) predict progression free (PFS) and overall survival (OS) in patients with metastatic colorectal cancer

C. Punt, G. Doyle, M. Miller, 2007 .

Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.

Richard G. Moore, R. Bast, W. J. Allard, 2008, Gynecologic oncology.

Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.

Robert W Veltri, Alan W Partin, A. Partin, 2002, The Journal of urology.

Value of computer-assisted quantitative nuclear grading in differentiation of normal urothelial cells from low and high grade transitional cell carcinoma.

R W Veltri, R. Veltri, Eva M. Wojcik, 1998, Analytical and quantitative cytology and histology.

Circulating tumor cells versus imaging : Predicting overall survival in metastatic breast cancer. Commentary

G. Sledge, D. Hayes, A. Stopeck, 2006 .

Statistical considerations for enumeration of circulating tumor cells

Leon W M M Terstappen, M. Miller, L. Terstappen, 2007, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Long‐Term assessment of prostate cancer progression free survival: Evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis

A. Partin, J. Epstein, E. Humphreys, 2008, The Prostate.

Combining clinical assessment and the Risk of Ovarian Malignancy Algorithm for the prediction of ovarian cancer.

Richard G. Moore, S. Skates, J. Ball, 2014, Gynecologic oncology.

RNA-Binding Motif 3 Protein Expression and Nuclear Architecture Changes as a Combined Biomarker to Predict Aggressive and Recurrent Prostate Cancer.

M. Miller, R. Veltri, C. Davis, 2017 .

HE4 and CA125 serum biomarker monitoring in women with epithelial ovarian cancer.

Richard G. Moore, G. Lambert-Messerlian, M. Miller, 2022, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.